Company Profile
Immunic Stock Price, News & Catalysts
- Ticker:
- IMUX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Germany
Stock performance
7.82 USD (-3.10%)
Close
Last updated: October 6, 2026
199M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, IMUX closed down 3.10% at $7.82. No new same-company headline was identified in the current news window.
Company overview
Oral Neurology Drug Developer
Immunic develops oral small molecules for chronic neurological diseases. Its lead program combines immunometabolic effects with a mechanism intended to support neuronal survival and slow disability progression.
Vidofludimus Calcium
Vidofludimus calcium is an oral DHODH inhibitor and Nurr1 activator. The dual mechanism is designed to reduce activated immune-cell activity while directly addressing pathways associated with neuroprotection.
Relapsing Multiple Sclerosis Program
The twin Phase 3 ENSURE-1 and ENSURE-2 trials are evaluating time to first relapse in relapsing multiple sclerosis. A synchronized analysis is intended to provide a coordinated registrational dataset if efficacy and safety are positive.
Progressive Multiple Sclerosis Strategy
The Phase 2 CALLIPER study evaluated vidofludimus calcium in progressive multiple sclerosis and generated biomarker and disability-progression data. Immunic is using those findings to design a confirmatory Phase 3 program in progressive disease.
Oral Pipeline Platform
Additional programs include IMU-856, which targets SIRT6 and is being explored in gastrointestinal and other diseases. The pipeline preserves optionality beyond multiple sclerosis while the company prioritizes late-stage execution.
IMU-856 SIRT6 Program
IMU-856 is intended to restore intestinal-barrier function without broadly suppressing the immune system. Clinical work has included celiac disease, and the mechanism may support development in other gastrointestinal disorders.
Future catalysts
- Topline results from the Phase 3 ENSURE relapsing multiple sclerosis program by the end of 2026.
- Initiation of a Phase 3 progressive multiple sclerosis trial in the second half of 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immunic (IMUX)?
Immunic (IMUX) most recently closed at 7.82 USD, a -3.10% move versus the previous session.
What is the market cap of Immunic (IMUX)?
Immunic currently has a market capitalization of 199M USD on BioPharmSignal.
What does Immunic do?
Oral Neurology Drug Developer Immunic develops oral small molecules for chronic neurological diseases. Its lead program combines immunometabolic effects with a mechanism intended to support neuronal survival and slow disability progression. Vidofludimus Calcium Vidofludimus calcium is an oral DHODH inhibitor and Nurr1 activator. The dual mechanism is...
On which exchange is IMUX stock listed?
Immunic (IMUX) is associated with NASDAQ, Germany, Biopharma.
What is ENSURE-1?
Relapsing Multiple Sclerosis Program The twin Phase 3 ENSURE-1 and ENSURE-2 trials are evaluating time to first relapse in relapsing multiple sclerosis.
Which conditions is Immunic targeting with ENSURE-1?
Immunic is associated with metabolic disease, neurology based on its company overview and current catalyst commentary.
How does Immunic describe recent progress with ENSURE-1?
Topline results from the Phase 3 ENSURE relapsing multiple sclerosis program by the end of 2026. Initiation of a Phase 3 progressive multiple sclerosis trial in the second half of 2026.
What is ENSURE-2?
Relapsing Multiple Sclerosis Program The twin Phase 3 ENSURE-1 and ENSURE-2 trials are evaluating time to first relapse in relapsing multiple sclerosis.